Faruqi and Faruqui, LLP Logo
Share this page

Meridian Bioscience, Inc. (VIVO)

NASDAQ:VIVO

Summary

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Meridian Bioscience, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Meridian Bioscience, Inc. (“Meridian” or the “Company”) (NASDAQ:VIVO).

The investigation focuses on whether the Company and its executives violated federal securities laws.  Specifically, on July 13, 2017, the U.S. Food and Drug Administration (“FDA”) issued a press release regarding Meridian’s subsidiary, Magellan Diagnostics (“Magellan”).  The FDA stated, in part, that an on-site inspection of Magellan’s facility in North Billerica, Massachusetts had identified nine observations that could potentially be violations of federal law.  Furthermore, the FDA stated that it will carefully review the evidence to determine if further action is necessary.

If you invested in Meridian stock or options and would like to discuss your legal rights, please fill out the form below.  There is no cost or obligation to you.  You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.

Request Information

Please tell us about yourself by completing the form and we will provide you with additional
information on how to join the Class Action at no cost to you.

  • Case:
    Meridian Bioscience, Inc. (VIVO)
  •    

* The submission of this form does not create an attorney-client relationship.

Contact Counsel

Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330

Email:

Case Details

Date:

  • 07/13/2017

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.